Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
The efficacy of combination therapy with 5-flucytosine and an IgG1 monoclonal antibody to Cryptococcus neoformans capsular glucuronoxylomannan was studied in vitro with J774. 16 murine macrophage-like cells and in vivo in murine cryptococcal infection. The combination of 5-flucytosine and IgG1 was more effective in reducing the numbers of C. neoformans colony-forming units in vitro and in vivo than either agent alone.
Feldmesser
M
M
Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Mukherjee
J
J
Casadevall
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D003453:Cryptococcosis / Q000188:drug therapy / Q000628:therapy*; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005437:Flucytosine / Q000494:pharmacology*; D007074:Immunoglobulin G / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D008805:Mice, Inbred A; D008826:Microbial Sensitivity Tests; D010587:Phagocytosis / Q000187:drug effects; D011134:Polysaccharides / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D007074:Immunoglobulin G; D011134:Polysaccharides; C027478:glucuronoxylomannan; D005437:Flucytosine